Long-term outcomes of alemtuzumab-based reduced-intensity conditioned hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia secondary to myelodysplastic syndrome. (2014)

First Author: Potter VT
Attributed to:  MRC Centre for Transplantation funded by MRC


No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.bbmt.2013.10.021

PubMed Identifier: 24216184

Publication URI: http://europepmc.org/abstract/MED/24216184

Type: Journal Article/Review

Volume: 20

Parent Publication: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

Issue: 1

ISSN: 1083-8791